Pharmacology in complex populations
It is essential that drugs are studied in the populations who will receive these drugs, that the studies are done ethically and efficiently and that capacity is built in the regions of the world where the diseases requiring drug treatment are prevalent. I focus primarily on drug exposure in pregnancy and breastfeeding (and to the infant) and the work requires clinical trials, observational studies, pharmacokinetic modelling (both PBPK and population PK), bioanalysis in appropriate body fluids and public engagement and involvement.

Drug drug interactions
Many key diseases co-exist and it is important to understand how the use of one drug can impact on the exposure of another drug given at the same time. I am Chief Investigator on the EDCTP-funded VirTUAL consortium which combines pharmacokinetic modelling, plasma and intracellular pharmacokinetic analysis, a clinical trial and observational pharmacokinetic studies in order to understand interactions between second-line antiretroviral therapy and first-line TB treatment.

Public engagement
Whilst public engagement and involvement is a component of all of my funded projects, there is a specific need to listen, co-create and innovate in partnership, particularly for complex and understudied groups. Wellcome Public Engagement enrichment award, ATtaining EQUity of Access TO Research (At The EQUATOR) is furthering this agenda.